World Journal of
Pharmaceutical and Life Sciences

MACULAR TELANGIECTASIA TYPE 2: INTEREST OF INTRAVITREAL INJECTIONS OF ANTI-VEGF

H. Okieh*, K. F. Oummarou Sambou, I. Jeddou, A. Fiqhi, Khooya A., Y. Bouabid, Y. Mouzari and A. Oubaaz

ABSTRACT

Introductiona: Type 2 macular telangiectasias are juxtafoveal capillary abnormalities, often bilateral, that become symptomatic when they cause cystoid macular edema. Initially considered a vascular disease, they are now seen as a neurodegenerative disease. Clinical Observation: The case studied is that of a 53-year-old woman with no notable ophthalmological history, presenting a progressive decline in visual acuity for one year. The examination reveals a corrected visual acuity of 4/10 in the left eye (LO) and 9/10 in the right eye (RO), with mild hyperopia in both eyes. The fundus shows dilation and tortuosity of the perimacular vessels in the LO. Treatment and Conclusion: The aim of the study is to evaluate the efficacy of anti-VEGF injections to treat type 2 macular telangiectasia. The results suggest that these injections are not effective on the proliferative form but it seems that encapsulated cell therapy secreting CNTF may be beneficial to reduce macular edema and improve visual acuity.

[Full Text Article]   [Download Certificate]